<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837876</url>
  </required_header>
  <id_info>
    <org_study_id>VICC GI 0815</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VICC-GI-0815</secondary_id>
    <nct_id>NCT00837876</nct_id>
  </id_info>
  <brief_title>Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking
      blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib
      works in treating patients with pancreatic cancer that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the efficacy of sorafenib tosylate in combination with erlotinib
           hydrochloride in patients with unresectable pancreatic cancer.

      Secondary

        -  To determine the response rate in patients treated with this regimen.

        -  To determine the progression-free survival of patients treated with this regimen at 4
           months.

        -  To evaluate the safety profile of this regimen in these patients.

        -  To evaluate the change in serum Ca 19-9 levels at baseline and at 8-week intervals.

        -  To evaluate the plasma proteomic profile at baseline and at 8 weeks to correlate with
           clinical parameters in order to identify potential prognostic or predictive markers.

        -  To analyze single-nucleotide polymorphisms on DNA obtained from pretreatment blood
           samples to evaluate toxicity and response to erlotinib hydrochloride.

      OUTLINE: Patients receive oral sorafenib tosylate once or twice daily and oral erlotinib
      hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      Serum samples are collected at baseline and at 8-week intervals to measure Ca 19-9 levels,
      and plasma and buffy coat samples are collected at baseline and at week 8 for proteomic
      assessment and genotyping of single-nucleotide polymorphisms associated with response and
      toxicity to erlotinib hydrochloride.

      After completion of study treatment, patients are followed up every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Progression-free Survival</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>Number of patients with progression-free survival at 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>at 4 months</time_frame>
    <description>Per RECIST criteria v. 1.0: measurable lesions: CR disappearance of target lesions, PR &gt; 30% decrease in the sum of the longest diameter (LD) of target lesions, PD &gt; 20% increase in the sum of the LD of target lesions or appearance of new lesions, SD neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Progression-free Survival</measure>
    <time_frame>at 4 months</time_frame>
    <description>Participants with progression-free survival at 4 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Worst Grade Toxicities</measure>
    <time_frame>every 4 weeks and every 8 weeks in follow-up to resolution of toxicity</time_frame>
    <description>Number of patients with worst-grade toxicity at each of five grades (grade 1 to 5, with 5 most severe) following NCI Common Toxicity Criteria: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib + Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg taken by mouth 1 time per day.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinb</intervention_name>
    <description>150 mg taken by mouth 1 time per day.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Microscopically confirmed diagnosis of pancreatic adenocarcinoma

               -  Unresectable disease

               -  No neuroendocrine tumors or cystadenocarcinoma

          -  Measurable or evaluable disease by RECIST criteria

          -  No known brain metastases

               -  Patients with neurological symptoms must undergo a CT scan/MRI of the brain to
                  exclude brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)

          -  Creatinine ≤ 1.5 times ULN

          -  INR &lt; 1.5 or PT/PTT normal unless patients are receiving anticoagulation treatments

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier contraception before, during, and for at
             least 6 months after completion of study treatment

          -  Able to swallow whole pills

          -  No patients who currently smoke

          -  No cardiac disease, including any of the following:

               -  NYHA class III-IV congestive heart failure

               -  Unstable angina (anginal symptoms at rest)

               -  New-onset angina (began within the past 3 months)

               -  Myocardial infarction within the past 6 months

               -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  No uncontrolled hypertension defined as systolic BP &gt; 150 mm Hg or diastolic BP &gt; 90
             mm Hg despite optimal medical management

          -  No arterial thrombotic or embolic events (e.g., cerebrovascular accident, including
             transient ischemic attacks) within the past 6 months

          -  No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 in the past 4 weeks

          -  No other hemorrhage/bleeding event ≥ CTCAE grade 3 in the past 4 weeks

          -  No significant traumatic injury in the past 4 weeks

          -  No known untreated malabsorption problem (e.g., ulcerative colitis, Crohn's disease)

          -  No known HIV positivity or chronic hepatitis B or C

          -  No known or suspected allergy to sorafenib tosylate or erlotinib hydrochloride

          -  No active clinically serious infection &gt; CTCAE grade 2

          -  No serious non-healing wound, ulcer, or bone fracture

          -  No evidence or history of bleeding diathesis or coagulopathy (except for
             cancer-related blood clots)

          -  No dermatitis ≥ CTCAE grade 2 at baseline

          -  No patients who currently smoke

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment with antiangiogenics (e.g., bevacizumab, thalidomide, marimastat,
             interferon alfa, vatalanib, vandetanib, ZD6126, sorafenib, semaxanib, sunitinib,
             axitinib)

          -  No more than one line of prior therapy for metastatic disease

          -  More than 4 weeks since prior major surgery or open biopsy

          -  No concurrent strong CYP34A inhibitors or inducers

          -  Concurrent warfarin or heparin allowed with the approval of the principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan D. Berlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Purchase Cancer Group - Paducah</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Cancer Center at Erlanger Hospital - Baroness</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Regional Cancer Center at Baptist Riverside</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <results_first_submitted>April 2, 2012</results_first_submitted>
  <results_first_submitted_qc>August 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2012</results_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Jordan Berlin, MD</investigator_full_name>
    <investigator_title>Professor of Medicine; Clinical Director, GI Oncology Program; Director, Phase I Program; Medical Director, Clinical Trials Shared Resources; Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled patients from October 2008 until February 2011.</recruitment_details>
      <pre_assignment_details>37 patients consented and went on study. Six patients were ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Sorafenib + Erlotinib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Sorafenib + Erlotinib</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Progression-free Survival</title>
        <description>Number of patients with progression-free survival at 8 weeks</description>
        <time_frame>at 8 weeks</time_frame>
        <population>Patients who received treatment for &gt;= 8 weeks. 14 study patients were treated for &lt; 8 weeks due to toxicity (5), disease progression (5), did not receive study drug (1), respiratory failure (1), drug held more than 28 days (1), patient withdrawal (1). The remaining 13 participants did not have a progression-free survival at 8 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Sorafenib + Erlotinib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Progression-free Survival</title>
          <description>Number of patients with progression-free survival at 8 weeks</description>
          <population>Patients who received treatment for &gt;= 8 weeks. 14 study patients were treated for &lt; 8 weeks due to toxicity (5), disease progression (5), did not receive study drug (1), respiratory failure (1), drug held more than 28 days (1), patient withdrawal (1). The remaining 13 participants did not have a progression-free survival at 8 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Per RECIST criteria v. 1.0: measurable lesions: CR disappearance of target lesions, PR &gt; 30% decrease in the sum of the longest diameter (LD) of target lesions, PD &gt; 20% increase in the sum of the LD of target lesions or appearance of new lesions, SD neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions</description>
        <time_frame>at 4 months</time_frame>
        <population>Participants who received treatment for 4 or more months. The remaining 10 participants received treatment for less than 4 months and were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Sorafenib + Erlotinib</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Per RECIST criteria v. 1.0: measurable lesions: CR disappearance of target lesions, PR &gt; 30% decrease in the sum of the longest diameter (LD) of target lesions, PD &gt; 20% increase in the sum of the LD of target lesions or appearance of new lesions, SD neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions</description>
          <population>Participants who received treatment for 4 or more months. The remaining 10 participants received treatment for less than 4 months and were not evaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Progression-free Survival</title>
        <description>Participants with progression-free survival at 4 months.</description>
        <time_frame>at 4 months</time_frame>
        <population>Patients with progression-free survival at 4 months. The remaining 17 patients were not available for evaluation at 4 months due to toxicity (5), disease progression (5), patient withdrawal (1),respiratory failure (1), study drug held more than 28 days (1), and no study drug (1.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Sorafenib + Erlotinib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Progression-free Survival</title>
          <description>Participants with progression-free survival at 4 months.</description>
          <population>Patients with progression-free survival at 4 months. The remaining 17 patients were not available for evaluation at 4 months due to toxicity (5), disease progression (5), patient withdrawal (1),respiratory failure (1), study drug held more than 28 days (1), and no study drug (1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Worst Grade Toxicities</title>
        <description>Number of patients with worst-grade toxicity at each of five grades (grade 1 to 5, with 5 most severe) following NCI Common Toxicity Criteria: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death.</description>
        <time_frame>every 4 weeks and every 8 weeks in follow-up to resolution of toxicity</time_frame>
        <population>All patients who received treatment with the study drugs. One patient did not receive treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Sorafenib + Erlotinib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Worst Grade Toxicities</title>
          <description>Number of patients with worst-grade toxicity at each of five grades (grade 1 to 5, with 5 most severe) following NCI Common Toxicity Criteria: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death.</description>
          <population>All patients who received treatment with the study drugs. One patient did not receive treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of patients with worst grade toxicity - 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of patients with worst grade toxicity - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of patients with worst grade toxicity - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of patients with worst grade toxicity - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of patients with worst grade toxicity - 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Sorafenib + Erlotinib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>pain in abdomen</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hemorrhage, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>obstruction, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>distension, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>pain in stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, NOS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>death - NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>pain, right upper quadrant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>edema, limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection with unknown ANC, artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>infection, normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>infection, Hickman catheter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>infection with unknown ANC, blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>infection with unknown ANC, wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>infection with unknown ANC, lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>calcium, serum-low-hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hypochloremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>ammonia level increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in back</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>pulmonary, upper respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="21" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>pain, abdomen NOS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="42" subjects_affected="22" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>edema limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>constitutional symptoms, other</sub_title>
                <counts group_id="E1" events="21" subjects_affected="7" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever (in the absence of neutropenia , where neutropenia is defined as ANC&lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alkaline phosphatase</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" events="33" subjects_affected="17" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="19" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hyponatremia-sodium, low</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>albumin, serum-low</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>glucose, serum-high-hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory, other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain, back</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>pain, headaches</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>dysarthria/voice changes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain-chest/thorax</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain-sinus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>pain-throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC-upper airway NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash-acne/acneiform</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>rash-hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>sweating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>dermatology/Skin, other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pruritis, itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordan Berlin, MD</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <phone>615-343-4128</phone>
      <email>jordan.berlin@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

